DCG-IV

• Description:

  DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1R/5R=389/630 μM) and III receptors (IC50: mGlu4R/6R/7R/8R= 22.5/39.6/40.1/32 μM) . DCG-IV has anticonvulsive and neuroprotective effects[1][2].

• UNSPSC:

  12352211

• Hazard Statement:

  H302, H319

• Target:

  MGluR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/dcg-iv.html

• Purity:

  99.0

• Solubility:

  H2O : ≥ 20 mg/mL

• Smiles:

  O=C([C@H]1[C@H](C(O)=O)C1[C@H](N)C(O)=O)O

• Molecular Formula:

  C7H9NO6

• Molecular Weight:

  203.15

• Precautions:

  H302, H319

• References & Citations:

  [1]Brabet I, et al. Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all clonedmetabotropic glutamate receptor subtypes. Neuropharmacology. 1998 Aug;37 (8) :1043-51.|[2]Bertrand HO, et al. Common and selective molecular determinants involved in metabotopic glutamate receptoragonist activity. J Med Chem. 2002 Jul 18;45 (15) :3171-83.|[3]Uyama Y, et al. DCG-IV, a potent metabotropic glutamate receptor agonist, as an NMDA receptor agonist in the rat cortical slice. Brain Res. 1997 Mar 28;752 (1-2) :327-30.|[4]Tomita N, et al. The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP) -induced locomotion and behavioral changes in mice. Ann N Y Acad Sci. 2000 Sep;914:284-91.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  MGluR1; mGluR2; mGluR3; mGluR4; mGluR5; mGluR6; mGluR7; mGluR8

• CAS Number:

  [147782-19-2]